Borje S. Andersson MD

PubMed

• Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience.
  Jitesh D Kawedia, Victoria W Handy, Alan L Myers, Alison M Gulbis, Rohtesh Mehta
  Transplantation and Cellular Therapy. 2025-09-01
• HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORS.
  Yago Nieto, John F Ward, Wayne Hofstetter, David Rice, Jose A Karam
  Clinical Cancer Research. 2025-08-25
• Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-labe...
  Ivetta Danylesko, Avichai Shimoni, Abraham Avigdor, Meirav Kedmi, Irina Amitai
  British Journal of Haematology. 2025-08-01

Journal Articles

• Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...  
  Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature

Abstracts/Posters

• Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell ...
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018